Semax
Semax
Multi-buy savings: save 4% on 2+ items and 6% on 3+. Applied automatically in your cart.
Couldn't load pickup availability
- Same-day dispatch on orders before 2pm, Royal Mail Tracked
- Free UK shipping on orders over £100
- Certificate of Analysis with every order · View CoA
- Independent test: Janoshik Analytical, March 2026 · View report
- For in vitro laboratory research use only
Concentration calculator
For laboratory calculation only. Not for human or veterinary use.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the ACTH(4-7) fragment, with a C-terminal Pro-Gly-Pro extension that confers improved metabolic stability over the parent peptide. Developed originally in Russia, it is widely studied for its role in BDNF (brain-derived neurotrophic factor) upregulation, neuroprotective signalling, and modulation of the hypothalamic-pituitary-adrenal (HPA) axis.
Preclinical research has investigated Semax in stroke models, ischaemia-reperfusion studies, cognitive function, and memory consolidation pathways. Its ACTH-derived structure enables interaction with melanocortin receptors (MC2R/MC4R), while the Pro-Gly-Pro extension increases peptidase resistance versus the parent ACTH(4-7) fragment.
Specifications
| CAS | 80714-61-0 |
|---|---|
| Formula | C37H51N9O10S |
| MW | 813.9 g/mol |
| Purity | ≥98% HPLC |
| Format | Lyophilised powder |
| Storage | −20 °C |
Research areas
- BDNF upregulation
- Neuroprotection
- Cognitive & memory function
- ACTH-receptor pharmacology
- HPA axis modulation
- Stroke & ischaemia models
Selected literature
Research Use Only. Supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary administration. Not evaluated by the MHRA or FDA for therapeutic use. Researchers must comply with the Human Medicines Regulations 2012 and all applicable institutional guidelines. Peptide Biosciences accepts no liability for use outside a controlled research context.
Share
